16th International Symposium on EBV and Associated Diseases (Brisbane Convention and Exhibition Centre)

15th July, 2014 (Tuesday)
2.00-5.00PM Registration at Brisbane Convention Centre (Ground Floor, Grey Street Entrance, South Bank)

16th July, 2014 (Wednesday)
7.30AM-5.00PM Registration at Brisbane Convention Centre (Plaza level, P7, Grey Street, South Bank)

Session I: Inaugural Address (Chair: Denis Moss)
8.45 – 8.50AM Welcome (Rajiv Khanna)
8.50 – 9.00AM Address by Professor Frank Gannon, Director of the QIMR Berghofer Medical Research Institute
9.00-9.45AM Inaugural Address Prof Emeritus Harald zur Hausen – Are some cancer and chronical diseases zoonoses?
9.45-10.00AM Denis Moss - Early days of EBV research at QIMR
10.00-10.30AM Morning Tea (Plaza Level, BCEC)

Session II: Burkitt Lymphoma (Chairs: Alan Rickinson and Joe Pagano)
10.30-11.00AM Professor Suzanne Cory - From translocations to therapy
11.00-11.20AM Ann Moormann - Prognostic and predictive biomarkers of endemic Burkitt lymphoma
11.20-11.32AM Alexander M Price - c-Myc Represses the LMP1 Promoter Early After Primary B-Cell Infection with EBV
11.32-11.44AM Leah Fitzsimmons - EBV as a survival factor in BL: how does a virus tip the apoptotic balance?
11.44-11.56AM  Robert M. DeKroon - Global proteomic changes induced by the Epstein-Barr virus oncoproteins LMP1 and LMP2A

11.56-12.08PM  Jeffrey A. Bailey - Characterization of EBV genome sequences derived from tumors obtained from Kenyan children diagnosed with endemic Burkitt lymphoma

12.08-12.20PM  Thibaut Deschamps - EBNA1 interacts with the chromatin-associated protein RCC1

12.20-12.32PM  Kay Osborn - Epstein Barr virus repression of host gene expression

12.35-1.30PM  Lunch (Plaza Level, BCEC)

Session III: Nasopharyngeal Carcinoma – Population studies and emerging therapies  
(Chairs: Allan Hildesheim and George Tsao)

1.30-1.50PM  Jaap Middledorp - Cytolytic virus activation therapy for Epstein-Barr virus driven tumours

1.50-2.02PM  Honglin Chen - Characterization of extracellular secreted Epstein-Barr virus BART microRNAs as serological markers for nasopharyngeal carcinoma diagnosis and treatment

2.02-2.14PM  Miao Xu - Targeted Sequencing and Characterization of Nasopharyngeal Carcinoma Associated Epstein-Barr virus Genomes

2.14-2.26PM  Fanny Wegner - Whole genome sequencing of EBV from blood reveals genotypic segregation of tumour-associated EBV

2.26-2.38PM  Anna E. Coghill - Potentially neutralizing antibodies against EBV glycoprotein 350 may be associated with a lower risk of developing incident nasopharyngeal carcinoma

2.38-2.50PM  Guokai Feng - Targeting of integrin alpha 6 eradicates nasopharyngeal carcinoma stem cell

2.50-3.02PM  Yufeng Chen - Evaluating Epstein-Barr viral DNA load in the nasopharynx of a NPC high-risk population
3.05-3.30PM  Afternoon Tea (Plaza Level, BCEC)

Session IV: EBV-B cell interaction
(Chairs: Erle Robertson and Micah Luftig)

3.30-4.00PM  Prof Klaus Rajewsky - Hodgkin Lymphoma and modeling EBV pathologies in mice

4.00-4.20PM  Paul Liberman - Viral reprogramming of the Daxx-histone H3.3 chaperone during EBV pre-latent infection

4.20-4.32PM  Magdalena Hagn - B cell-derived Granzyme B is associated with acute EBV infection

4.32-4.44PM  Jens S. Kalchschmidt - EBNA3C induces activation-induced cytidine deaminase (AID) expression and somatic hypermutation (SHM) in EBV-infected primary B cells and LCLs

4.44-4.56PM  Danielle Westhoff Smith - Epstein Barr Virus Nuclear Antigen 1 (EBNA1) provides multiple survival advantages to EBV-infected cells by regulating cellular gene expression

4.56-5.08PM  Andrew Bell - Epstein-Barr virus reactivation following stem cell transplantation is associated with the early emergence of circulating CD27+ memory B cell

Welcome drinks celebrating 50 years of EBV discovery
Poster Session – I
5.30-7.00PM
17th July, 2014 (Thursday)

7.30AM-5.00PM Registration at Brisbane Convention Centre (Plaza level, P7, Grey Street, South Bank)

Session V: Primary EBV Infection – Immune regulation and pathogenesis (Chairs: Paul Liberman and Andrew Hislop)

8.30-8.50AM Alan Rickinson - Infectious mononucleosis: more questions than answers

8.50-9.10AM Philip Stevenson - Tracking a gamma-herpesvirus to B cells

9.10-9.22AM Lisa Selin - Severity of infectious mononucleosis (IM) correlates with the frequency of crossreactive influenza A virus (IAV)-M1 and Epstein Barr virus (EBV)-BMLF-1-specific CD8 T cells

9.22-9.34AM Ayman El-Guindy - A locus encompassing the Epstein-Barr virus BGLF4 kinase regulates expression of genes encoding viral structural proteins

9.34-9.46AM Kin-Hang Kok - Modulation of innate antiviral response by a single Epstein-Barr virus-encoded microRNA

9.46-9.58AM Chiara Rancan - Immunomodulatory functions of LMP2A

9.58-10.10AM Eric Johannsen - The EBNA3 family of Epstein-Barr virus nuclear proteins associates with the USP46/USP12 deubiquitination complexes to regulate lymphoblastoid cell line growth

10.10-10.22AM Chun-kui Shao - Expression of CCL21 on EBV-associated gastric carcinoma cells recruits and protects CD8+CCR7+ T lymphocytes from apoptosis

10.30-11.00AM Morning Tea (Plaza Level, BCEC)

Session VI: Vaccines and Antiviral Therapeutics (Chairs: Jeff Cohen and Alison Sinclair)

10.30-10.50AM Jeff Cohen - Development of a Prophylactic Vaccine for EBV
10.50-11.10 AM  Arnd Kieser - High throughput screening for inhibitors of the LMP1-TRAF2 complex identifies a new compound that counteracts LCL survival

11.10-11.22 AM  Troy E. Messick - Development of Small Molecule Inhibitors of EBNA1 for the Treatment of EBV-Associated Disease

11.22-11.34 AM  Kwai Fung Hui - Inhibition of class I histone deacetylases (HDACs) by HDAC inhibitors leads to the induction of Epstein-Barr virus lytic cycle in EBV-positive epithelial malignancies

11.34-11.46 AM  Chi Man Tsang - The importance of IL-6/IL-6R/STAT3 signaling in the progression of NPC: a window for therapeutic targets?

11.46-11.58 AM  Tong-Ming Fu - A Replication Defective Vaccine for Herpesvirus

---

**Session VII: EBV and Lymphogenesis**
*(Chairs: Emmanuel Wiertz and Scott Burrows)*

12.00-12.20PM  Lori Frappier - A Mechanism by which EBNA1 Promotes EBV Latency and Identification of EBV Cell Cycle Regulators

12.20-12.40PM  Shannon Kenney - An Epstein-Barr virus mutant missing Latent membrane protein 1 (LMP1) requires CD4+ T cells and CD40 stimulation for lymphomagenesis

12.40-12.55PM  Michelle West - Host cell reprogramming through selective gene targeting and modulation of enhancer looping by Epstein-Barr virus nuclear antigens

12.55-1.10PM  Paul J Farrell - A single amino acid in EBNA2 determines superior B cell growth functions of type 1 EBNA2

1.10-2.00PM  Lunch (Plaza Level, BCEC)

---

**Session VIII: EBV Replication and Reactivation**
*(Chairs: Andy Bell and Christian Munz)*

2.00-2.20PM  Sankar Swaminathan – Mechanisms and specificity of gene regulation by the essential lytic replicative phase proteins EBV SM and KSHV ORF57 during gamma herpesvirus replication
1. **Session IX: Molecular Aspects of EBV Pathogenesis**
   
   **Chair: Lindsey Hutt-Fletcher**
   
   **4.00-4.20PM**  
   **George Tsao** - Biology of EBV infection in nasopharyngeal epithelial cells
   
   **4.20-4.40PM**  
   **Emmanuel Wiertz** - Identification of novel target genes of Epstein Barr Virus miRNAs
   
2. **Henle Lecture**
   
   **Chair: Denis Moss**
   
   **4.40-5.30PM**  
   **Cliona Rooney** – Advancing T-cell therapies for EBV-associated diseases
   
3. **Poster Session – II**
   
   **5.30-7.00PM**
18th July, 2014 (Friday)

7.30AM-5.00PM Registration at Brisbane Convention Centre
(Plaza level, P7, Grey Street, South Bank)

**Session X: Latent EBV Immune regulation**
*(Chairs: Ingemar Ernberg and Corey Smith)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.30-8.50AM</td>
<td>Christian Munz</td>
<td>Innate and adaptive immune control of Epstein Barr virus in vivo</td>
</tr>
<tr>
<td>8.50-9.10AM</td>
<td>Andrew Hislop</td>
<td>Virological and immunological events in asymptomatic primary EBV infection</td>
</tr>
<tr>
<td>9.10-9.22AM</td>
<td>Carrie B. Coleman</td>
<td>Epstein-Barr virus Type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines</td>
</tr>
<tr>
<td>9.22-9.34AM</td>
<td>Maaike Ressing</td>
<td>Epstein-Barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with Toll-like receptor signaling</td>
</tr>
<tr>
<td>9.34-9.46AM</td>
<td>Wenwei Tu</td>
<td>Targeting human gamma delta-T cells controls Epstein-Barr virus-induced B cell lymphoproliferative disease in humanized mice</td>
</tr>
<tr>
<td>9.46-9.58AM</td>
<td>John Miles</td>
<td>Understanding antigen-driven T cell selection dynamics during Epstein-Barr virus infection</td>
</tr>
<tr>
<td>9.58-10.13AM</td>
<td>Josef Mautner</td>
<td>Virion and autoantigen-specific CD4+ T cells in the control of EBV infection</td>
</tr>
<tr>
<td>10.13-10.28AM</td>
<td>Mainthan Palendira</td>
<td>An occupying force of memory T cells against Epstein Barr Virus</td>
</tr>
<tr>
<td>10.30-11.00AM</td>
<td>Morning Tea</td>
<td>Morning Tea (Plaza Level, BCEC)</td>
</tr>
</tbody>
</table>

**Session XI: Clinical Aspects of EBV-associated malignancies**
*(Chairs: Cliona Rooney and John Miles)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00-11.30AM</td>
<td>Helen Heslop</td>
<td>Rapidly Available EBV Specific T cells</td>
</tr>
</tbody>
</table>
11.30-12.00PM  **Ralf Küppers** – Pathobiology of Hodgkin lymphoma and the role of EBV in lymphomagenesis

12.00-12.12AM  **Henry Sze** - Advances in the Clinical Management of Nasopharyngeal Cancer

12.12-12.24AM  **Wei-Hua Jia** - EBV oncomirs from nasopharyngeal brushing samples to diagnose Nasopharyngeal Carcinoma with high efficiency

12.24-12.36AM  **Corey Smith** - Treatment of Epstein-Barr Virus–Associated Nasopharyngeal Carcinoma with AdE1-LMPpoly Based Adoptive Immunotherapy

12.36-12.48AM  **Jiang Li** - Phase I Trial of Adoptively Transferred Tumor-infiltrating Lymphocyte Immunotherapy Following Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma

12.48-1.00PM  **Ida Ricciardelli** - Towards gene therapy for EBV-associated Post-Transplant Lymphoproliferative disease: genetically modified EBV-specific Cytotoxic T Lymphocytes induce regression of autologous EBV-induced Lymphoproliferation despite immunosuppression

1.00-2.00PM  Lunch (Plaza Level, BCEC)

**Session XII: EBV-Associated Genetic and Autoimmune disorders**

(Chair: Shannon Kenney)

2.00-2.20PM  **Stuart Tangye** – Primary immunodeficiencies as models to delineate requirements for anti-EBV immunity

2.20-2.40PM  **Michael Pender** - Treating multiple sclerosis with CD8+ T cells directed against EBV-infected B cells in the brain

**Session XIII: Molecular pathways in EBV Infection**

(Chairs: Paul Farrell and Josef Mautner)

2.40-2.52PM  **Janet Mertz** - Hypoxia-induced lytic reactivation of EBV requires both HIF-1α and activated p53

2.52-3.04PM  **Rob Verhoeven** - LMP1 mediated NF-kB signalling and BART miRNA expression form an auto-regulatory loop to maintain EBV latency in NPC
### Session XIV: EBV-Epithelial cell Interactions
(Chairs: John Nicholls and Michelle West)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.00-4.20PM</td>
<td>Lindsey Hutt-Fletcher</td>
<td>Epithelial cells in the cycle of persistence</td>
</tr>
<tr>
<td>4.20-4.32PM</td>
<td>Dhananjay M. Nawandar</td>
<td>KLF4 and BLIMP1 cooperate to induce lytic EBV reactivation during epithelial cell differentiation</td>
</tr>
<tr>
<td>4.32-4.44PM</td>
<td>Alan Kwok Shing Chiang</td>
<td>Genomic diversity of Epstein-Barr virus genomes isolated from primary nasopharyngeal carcinoma biopsies</td>
</tr>
<tr>
<td>4.44-4.56PM</td>
<td>Aron R. Marquitz</td>
<td>Profiling of EBV latent infection in AGS cells using next generation sequencing</td>
</tr>
</tbody>
</table>

### Session XV: Valedictory lectures
(Chair: Rajiv Khanna)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.00-5.20PM</td>
<td>Paul Farrell</td>
<td>Future perspectives on the molecular pathogenesis of EBV</td>
</tr>
<tr>
<td>5.20-5.40PM</td>
<td>Lawrence Young</td>
<td>Future prospects for novel therapeutics for EBV-associated diseases</td>
</tr>
</tbody>
</table>

### Conference Dinner at Brisbane Convention Centre
(Boulevard Room)
7.00-10.30PM

**Dinner Speech: Prof. Peter Doherty**

**EBV song: composed by Paul Farrell, Lawrence Young and Alan Rickinson**
19th July, 2014 (Saturday)

Visit to Lone Pine Sanctuary
9.00AM-1.30PM

Aussie BBQ lunch at Lone Pine Sanctuary

Buses leave from Brisbane convention centre at 8.45AM